Nutriband Reports Revenue Decline and Improved Net Loss for Three and Six Months Ended July 31, 2026

Nutriband Inc. reported its financial results for the three and six months ended July 31, 2026, revealing a significant decline in revenue compared to the same period in the previous year. The company generated revenue of $437,514 for the three months ending July 31, 2026, down from $622,452 in the same quarter of 2025. For the six-month period, revenue decreased to $870,913 from $1,289,884 year-over-year. The gross profit for the three months was $182,874, while for the six months, it was $378,675, reflecting a decrease in sales primarily due to a key customer moving operations overseas.

The company's total expenses for the three months ending July 31, 2026, were $1,328,151, leading to a loss from operations of $890,637, compared to a loss of $2,003,213 in the same quarter of the previous year. For the six months, the loss from operations was $2,144,988, down from $3,416,710 in the prior year. The net loss for the three months was $880,561, or $(0.07) per share, significantly improved from a net loss of $23,814,503, or $(2.12) per share, in the same quarter of 2025. The reduction in losses is attributed to decreased selling, general, and administrative expenses, which fell to $750,317 from $1,597,540 year-over-year.

Operationally, Nutriband has faced challenges, particularly in its Pocono Pharmaceuticals segment, which saw a decline in revenue due to the loss of a major customer. The company has also shifted its focus away from its 4P Therapeutics segment, resulting in no revenue from contract research and development services in the current year. The company reported a decrease in research and development expenses related to its Aversa Fentanyl product, which amounted to $322,194 for the three months ending July 31, 2026, down from $562,554 in the prior year.

As of July 31, 2026, Nutriband had cash and cash equivalents of $3,421,615, a decrease from $4,574,857 at the beginning of the fiscal year. The company reported working capital of $2,912,335, down from $4,204,437 as of January 31, 2026. The company continues to rely on financing activities to support its operations, having entered into a $5 million credit line agreement in July 2023 to fund research and development efforts.

Looking ahead, Nutriband's management remains cautiously optimistic about its ability to generate sufficient funds from operations to support its activities over the next twelve months. The company is focused on advancing its product development pipeline, particularly its Aversa technology, which aims to address the growing concerns around opioid abuse. However, the company acknowledges the inherent risks and uncertainties associated with drug development and regulatory approvals, which could impact its future financial performance.